Discontinue therapy if signs of myalgia, back pain, CK conc elevation or myopathy occur; if level of serum transaminase is >3x ULN. Increase in serum aminotransferase conc for transient & resolved or improved w/ continued or interrupted therapy. Perform liver function tests before & at 6, 12 wk after initiation of therapy, & every 6 mth in patients w/ long term use. Concomitant use w/ cyclosporin, fenofibrate, gemfibrozil, nicotinic acid, azole antifungal, macrolide antibacterial, HIV PIs, verapamil, diltiazem, amiodarone; colchicine especially in geriatric patients or w/ renal dysfunction. Increase risk of rhabdomyolysis in geriatric patients, hepatic or renal dysfunction, chronic alcoholism & hypothyroidism patients. Increased risk of myopathy in patients ≥65 yr, renal impairment, inadequately treated hypothyroidism. Risk of hyperglycemia is increased. Excessive alcohol consumption & history of liver disease. Interrupt therapy promptly if serious liver injury w/ hyperbilirubinemia or jaundice occurs. Obtain baseline CK conc prior to therapy, & measure CK conc in adults experiencing muscle symptoms during therapy. Temporarily withhold therapy in acute, serious condition suggestive of myopathy or predisposing development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine or electrolyte disorders, uncontrolled seizures).